Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.
Kissling E., Rose A., Emborg H-D., Gherasim A., Pebody R., Pozo F., Trebbien R., Mazagatos C., Whitaker H., Valenciano M., European Ive Group None.
Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.